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Abstract
Plasma fatty acid patterns were assessed by
gas liquid chromatography in 73 patients with
active inflammatory bowel disease and 107
healthy controls. The influence of the disease
activity on fatty acid profile was also investi-
gated. Plasma fatty acid patterns in patients
with ulcerative colitis and Crohn's disease
were similar. Plasma C18:3n3 and C22:6n3
were significantly higher in active ulcerative
colitis (p=0.0143 and p<0O00001 respectively)
and in Crohn's disease (p<0.00001 for both)
than in controls, whereas C20:3n6 was signific-
antly lower in patients than in controls, both in
ulcerative colitis (p=0.0001) and in Crohn's
disease (p=0.0041). In more severe disease,
plasma polyunsaturated fatty acid concentra-
tions fell with a significant stepwise decrease in
the desaturation index (p=0.0031 in ulcerative
colitis and p=0.0355 in Crohn's disease). Even
in patients with severe disease, however,
plasma n3 fatty acids (C18:3n3 and C22:6n3)
never fell below those of healthy controls.
These findings suggest that in active inflamma-
tory bowel disease, an increased biosynthesis
might coexist with an increased consumption
ofpolyunsaturated fatty acids. These observa-
tions may be of relevance in the pathogenesis
of the disease as polyunsaturated fatty acids
are involved in tissue eicosanoid synthesis and
cellular membrane function, including that of
immunocompetent cells. These results also
question the rationale of using n3 polyunsatur-
ated fatty acids in the treatment of inflamma-
tory bowel disease.
(Gut 1992; 33: 1365-1369)
Polyunsaturated fatty acids have essential bio-
logical functions. As part of the structure of cell
membrane, they exert control on its intrinsic
proteins - for example, enzymes, receptors - by
inducing changes in membrane fluidity.'2 In
addition, the long chain polyunsaturated fatty
acids, dihomo-T-linolenic (C20:3n6),3 arachi-
donic (C20:4n6),5 and eicosapentaenoic (C20:
5n3)6 acids are the precursors of eicosanoids.
Some of the arachidonic acid derived eicosanoids
(prostaglandin E2, leukotriene B4, and throm-
boxane A2) have been incriminated in the patho-
genesis of inflammatory bowel disease, because
their concentrations increase in the inflamed
intestinal mucosa in the acute phase of the
disease.7-2
There are four different polyunsaturated fatty
acid series which share the same desaturases and
elongases for their synthesis.'3 '4 Their affinity
for these enzymatic systems are different, how-
ever. In addition, the components of the differ-
ent fatty acid series are not interconvertible in
vivo.'3 These properties have allowed modifica-
tion of the eicosanoid synthesis by producing
changes in dietary polyunsaturated fatty
acids. 5`6 Dietary supplementation with eicosa-
pentaenoic and docosahexaenoic acids rich fish
oil induces the appearance of triene prostaglan-
dins and thromboxanes'78 and pentaene
leukotrienes'9 with attenuated inflammatory
effects.'7 '9 The therapeutic efficiency of eico-
sapentaenoic acid (C20:5n3) as an antiinflam-
matory agent in experimental models of
inflammation20 21 and therapeutic trials in patients
with rheumatoid arthritis22 and inflammatory
bowel disease23-25 is, however, at least,
controversial.
Plasma polyunsaturated fatty acid patterns
have not been previously assessed in ulcerative
colitis whereas information in Crohn's disease is
limited.2627 It would be of scientific interest to
know of plasma polyunsaturated fatty acids
profile in inflammatory bowel disease as it might
have both pathophysiological and therapeutic
implications.
The aim of this study was to prospectively
assess the plasma fatty acid pattern in patients
with active inflammatory bowel disease com-
pared with healthy controls and to ascertain
whether the activity of the disease has any
influence upon plasma concentrations of fatty
acids.
Methods
PATIENTS
Seventy three consecutive patients (40 men, 33
women) with active inflammatory bowel disease
(median age 32.5 years; ranges 14-81) were
included in the study at admission or when first
seen in the outpatient clinic. Forty one had
ulcerative colitis and 32 had Crohn's disease.
The diagnosis ofinflammatory bowel disease was
based upon clinical, endoscopic and radiological
findings and was supported by biochemical,
scintigraphic and pathological features. Exhaus-
tive microbiological analysis were performed in
order to exclude patients with gastrointestinal
infection. These included in all cases stool
culture, special stool culture and serologic tests
for Yersinia enterocolitica, repeated fresh stool
examination (three to six) for parasites and
chlamydia direct immunofluorescent test.
Clostridium difficile toxin assays, biopsy examina-
tion and culture for mycobacteria and immuno-
histochemical detection of herpes virus and
cytomegalovirus in biopsy specimens were
carried out in particular cases.
The activity of the disease was assessed by
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means of the Truelove's index for ulcerative
colitis28 and the Van Hees's index for Crohn's
disease.29 According to the activity index, the
attack was classified as mild, moderate, or
severe. Twelve patients with ulcerative colitis
had mild, 19 moderate, and 10 severe attacks. In
Crohn's disease, the activity was mild in 15,
moderate in 11, and severe in six patients. Data
regarding diet, nutritional status,30 and drugs
were also carefully recorded.
CONTROLS
One hundred and seven healthy individuals (46
men, 61 women; median age 32.5 years; ranges
18-76) living in an urban area in the outskirts of
Barcelona (Catalunya, Spain) acted as a control
group. All subjects were well nourished accord-
ing to previously described criteria.30 The exist-
ence ofboth acute and chronic illnesses was ruled
out on the basis of a complete anamnesis and
full clinical and biological examination includ-
ing routine haematological counts, serum
glycaemia, total cholesterol, triglycerides, and
renal and liver function tests (Technicon
SMA-20 Autoanalyzer). Those with previous
history of diseases or surgical procedures capable
of influencing the absorption of macro or micro-
nutrients were also excluded from the study. All
subjects, including elderly people, lived at their
family home and were on a balanced western
diet. Intake ofmonotonous, deficient, vegetarian
or lacto ovo vegetarian diets was ruled out.
Alcohol intake was lower than 40 g/day for men
and 20 g/day for women. Habitual drug intake in
TABLE I Clinicalfeatures ofthe patients
Ulcerative Crohn's
colitis disease
(n=41) (n=32)
Patients with first attack 139
Patients previously diagnosed
Intermittent attacks 18 7
Continuous symptoms 10 16
Duration of disease (months) 5-456 7-120
Nutritional status (30)
Good nutrition 25 12
Kwashiorkor like malnutrition 12 15
Marasmus 0 2
Mixed malnutrition 4 3
Previous surgery 0 4
Current drug therapy
Patients untreated 5 10
Steroids alone 22 9
Sulphasalazine alone 6 3
Metronidazole alone 0 3
Steroids+sulphasalazine 6 2
Steroids+metronidazole 1 4
Steroids+ metronidazole+ sulphasalazine 1 1
TABLE II Plasma fatty acids (FA) in ulcerative colitis (UC)
as compared with controls
% UC (n=41) Controls (n= 107) p
16:0* 26-9 (0.4) 25-2 (0.2) 0-0012
16:It 1-7[11-2.2] 1-7[1-5-1-9] 04703
18:Ot 8-2 [8-1-9-3] 10-5 [100-10-8] <0-000001
18:It 22-7 [20-5-24-8] 21-9 [20-9-22 8] 0-2870
18:2n6* 26-7 (0.7) 27-2 (0.4) 0-6293
18:3n3t 0.3 [000-51 00 [0 0 00] 0-0143
18:3n6t 0 0 [00-00] 0 0 [0 0-0 0] 0.5597
20:2n6t 00 [00-031 01 [00-003] 00711
20:3n6* 1 9(0-1) 2-6(0-1) 0-0001
20:4n6* 7-4(0.3) 8.0(0.2) 0-1320
20:5n3t 0-3 [00-005] 0-2 [00-004] 0-3414
22:6n3t 2-2[1-9-2-8] 1-4[13-1-6] <0 00001
UNID* 131-8(20) 131-5(1.1) 09060
*Mean (SEM) Student's t test; tMedian [95% CI].
Mann-Whitney U test; UNID=unsaturation index.
the previous three months of sample extraction
was carefully ruled out, especially for hypo-
lipemiant drugs, non-steroidal antiinflammatory
drugs or oral contraceptives. Individuals taking
trace elements or vitamin supplements in the
previous six months were not included. Relatives
ofpatients with inflammatory bowel disease were
also excluded.
Informed consent was obtained from each
patient. The study was performed in accordance
with the 1975 Declaration of Helsinki ethical
guidelines and was approved by the Research
and Ethical Committees of the Hospital.
PLASMA FATTY ACID ASSAY
In all patients and healthy controls, a 5 ml venous
blood sample for plasma fatty acid measurement
was drawn after a 14 hour overnight fast at the
same time that full clinical assessment was
performed. Plasma was separated by centrifuga-
tion at 3000xg during five minutes and immedi-
ately frozen and stored at - 50°C under nitrogen
atmosphere.
The plasma obtained was treated with 5 ml of a
chloroform:methanol (2:1 v/v) mixture contain-
ing 50 mg/l butylhydroxy-toluene, 1 5 ml 0.01 N
HCI, and 50 [11 MgCl2 in water. The mixture was
stirred for one minute in a tube mixer and then
centrifugated at 3000xg for 10 minutes. The
chloroform phase was separated by aspiration
with a Pasteur pipette, and the aqueous phase
was reextracted with 3 ml chloroform:methanol
mixture. After centrifugation, chloroform
phases were mixed and evaporated to dryness
under nitrogen atmosphere.'
Saponification and methylation of fatty acids
were immediately carried out, using 14% BF3 in
methanol according to the Morrison and Smith
procedure.32 Fatty acid methyl esters were
quantified by gas liquid chromatography in a
5890A Hewlett-Packard chromatograph using a
30-m, wide bore column, 0-32 mm internal
diameter, impregnated with SP-2330 as station-
ary phase. Initial oven temperature was 1500
which was maintained for eight minutes; after-
wards, it was increased at a rate of 3°/minute up
to 2 10°C. The identification and quantification of
fatty acid methyl esters was possible by using an
external standard (Sigma Co, St Louis, Mo,
USA). Individual response factors were calcu-
lated for each fatty acid.
Fatty acids from C14:0 to C22:6n3 were
measured. Unidentified peaks accounted for less
than 0.5% of total fatty acids. The desaturation
index was calculated as previously described`
according to the formula:
UNID= X (fatty acid percentage x number
of double bonds).
STATISTICAL ANALYSIS
For statistical analysis the Statistical Package for
Social Sciences SPSS/PC+ (SPSS Inc, Chicago,
Illinois, USA, 1985) was used."4 Variables with
normal distribution and homogeneous variance
were compared by means of parametric tests,
otherwise their non-parametric counterparts
were used. To assess differences in plasma fatty
acid percentages between patients and controls,
1366
 group.bmj.com on April 5, 2011 - Published by gut.bmj.comDownloaded from 
Plasma polyunsaturatedfatty acid pattern in active inflammatory bowel disease
the Student's t test or Mann-Whitney U test were
used, when necessary. One way analysis of
variance with 'a posteriori' Scheffe test or
Kruskall-Wallis one way analysis of variance by
ranks were used, when necessary, to assess the
influence of the severity of the disease upon fatty
acid profile in these patients. When the
Kruskall-Wallis test disclosed a significant p
value, the Mann-Whitney U test was carried out
in order to detect where the differences occur.
Results are expressed as mean (SEM) or median
and its 95% confidence interval35 for parametric
and non-parametric variables respectively.
Results
The clinical features of the 73 patients included
in the study are detailed in Table I. Ulcerative
colitis involved the entire colon in 21 patients,
the left colon in 12, and was confined to the
rectum in eight. Crohn's disease was ileocolic in
10 cases, involved only the small bowel in nine
patients, and 13 patients had colonic disease.
TABLE III Plasma fatty acids (FA) in Crohn's disease (CD)
as compared with controls
% CD (n=32) Controls (n= 107) p
16:0* 25-6 (0-3) 25-2 (0-2) 0-4372
16:11t 2-1 [1-6-2-8] 1-7 [1.5-1-9] 0.0725
18:0t 8-3 [7-8-9-4] 10-5 [10-0-10-8] <0-00001
18:It 23-4 [20-9-25.0] 21-9 [20-9-22-8] 0.0997
18:2n6* 25.8 (0.8) 27-2 (0-4) 0-1700
18:3n3t 0.7 [0-08-1-4] 0 0 [0 0-0 0] <0-00001
18:3n6t 0.0 [0 0-0.3] 0 0 [0 0-0 0] 0-1954
20:2n6t 0-0 [0 0-0 2] 0-1 [0 0-03] 0-0340
20:3n6* 2-1(0-1) 2-6 (0-1) 0-0041
20:4n6* 7-5(0-3) 8-0(0-2) 0-1920
20:5n3t 0-4 [00-0-7] 0-2 [0 0-0 4] 0-1725
22:6n3t 3.0 [1-7-3-8] 1-4 [1-3-1-6] <0-00001
UNID* 136-2(2-5) 131-5(1-1) 0-0980
*Mean (SEM) Student's t test; tMedian [95% CI].
Mann-Whitney U test; UNID=unsaturation index.
TABLE IV Plasma fatty acids (FA) in ulcerative colitis. Influence of the activity ofthe disease
% Mild (n= 12) Moderate (n= 19) Severe (n= 10) p
16:0* 25-7(1-1) 27-6(0-3) 27.0(0.6) 0-1605
16:1* 1-8(0.2) 1-9(0-3) 1-7(0-3) 0.8801
18:0t 9-8 [8-2-12-0] 8-2 [7 6-9.5] 8-1 [7-2-10-0] 0.02531t5
18:11t 18-8 [15-2-25-4] 22-7 [20.5-28-0] 25-1 [21-6-30-1] 0-0236t5
18:2n6* 27-3(1-3) 26-4(1-2) 26-8(1-4) 0-8845
18:3n3* 0-4 (0-1) 0-5 (0-1) 0-5 (0-2) 0-8647
18:3n6t 0-3 [00-08] 0-0 [00-00] 0-0 [00-02] 0-0013t5
20:2n6t 0-2 [0 0-0 5] 0-0 [0 0-0.3] 0.0 [0 0-05] 0-2554
20:3n6* 2-7(0-2) 1-6(0-1) 1-3(0-2) 0-0002t5
20:4n6* 8-8 (0-4) 6-6 (0-4) 7-2 (0-4) 0-0243::
20:5n3* 0-6(0-1) 0.3(0-1) 0-2(0-06) 0-0622
22:6n3* 2-9 (0-1) 2-1 (0-2) 2-2 (0-1) 0-0648
UNID* 142-0(3-0) 126-5(3-1) 129.6(2.2) 0-0031t
*Mean (SEM). One way analysis of variance+Scheffe test; tMedian [950% CI]. Kruskall-Wallis test+
Mann-Whitney U test; tMild v moderate; §Mild v severe; UNID=unsaturation index.
TABLE V Plasma fatty acids (FA) in Crohn's disease. Influence of the activity of the disease
% Mild (n= 15) Moderate (n= 11) Severe (n= 6) p
16:0* 25-2(0-4) 25-6(0-6) 26-3(1-2) 0-5419
16:1* 2-2(0-3) 2-8(1-0) 1-6(0-5) 0-2123
18:0* 9-1 (0-3) 8-5 (0-4) 7-9 (0-5) 0-2045
18: 1* 21-4 (1-0) 23-3 (0-8) 28-5 (2-5) 0-00641-
18:2n6* 26-1(1-2) 26-2(1-3) 24-7(1-9) 0-7929
18:3n3* 1-0 (0.2) 0-9 (0-2) 0-7 (0-3) 0-7644
18:3n6t 0-2[0-0-04]00- [0-0-03]0 0- [0-0-1-1] 0-3943
20:2n6t 0-2 [0-0-0-4] 0-0 [0-0-0-05] 0-0 [0-0-0-5] 0-0640
20:3n6* 2-3(0-2) 2-2(0-2) 1-3(0-2) 0-0641
20:4n6* 8-2 (0-5) 7-4 (0-4) 5-9 (0-5) 0-0443t
20:5n3* 0-6 (0-1) 0-3 (0-1) 0-2 (0-1) 0-0620
22:6n3* 3-1 (0-3) 2-5(0-4) 2-2(0-5) 0-3760
UNID* 142-0 (3-0) 134-4 (3-3) 124-9 (7-8) 0-0355t
*Mean (SEM). One way analysis of variance+Scheffe test; tMedian [950/o CI]. Kruskall-Wallis test+
Mann-Whitney U test; tMild v severe. UNID= unsaturation index.
Four patients with Crohn's disease who had
previous operations (three colectomies and one
ileocolectomy), were included because of relaps-
ing disease.
PLASMA FATTY ACIDS
Plasma percentages of the different fatty acids in
patients with ulcerative colitis and Crohn's
disease are shown in Tables II and III.
ULCERATIVE COLITIS (Table II)
The most striking finding in plasma fatty acid
profile in ulcerative colitis patients was the
marked increase in n3 polyunsaturated fatty
acids, both the essential precursor (ct-linolenic
acid (C18:3n3)) and the end product (docosa-
hexaenoic acid (C22:6n3)).
In the n6 series, patients with ulcerative colitis
showed low values of dihomo-T-linolenic acid
(C20:3n6), whereas values of the essential pre-
cursor (linoleic acid (C18:2n6)) and the main
product (arachidonic acid (C20:4n6)) showed no
differences when compared with controls.
Palmitic acid (C16:0) concentrations were
significantly higher in ulcerative colitis patients
than in healthy individuals. Stearic acid (C 18:0)
was significantly lower in ulcerative colitis than in
controls. There were no differences in mono-
enoic fatty acids between patients and controls.
The unsaturation index did not show differ-
ences between patients with ulcerative colitis and
controls.
CROHN S DISEASE
The plasma fatty acid profile in Crohn's disease
was similar to that found in ulcerative colitis
(Table III). As in ulcerative colitis, a significant
increase in n3 polyunsaturated fatty acids (cu-
linolenic acid (C18:3n3) and docosahexaenoic
acid (C22:6n3)) and a decrease in plasma
dihomo-T-linolenic acid (C20:3n6), a long chain
polyunsaturated fatty acids of the n6 series, was
also observed.
When compared with healthy individuals,
plasma concentrations of stearic acid (C 18:0) was
significantly decreased.
EFFECT OF THE ACTIVITY OF THE DISEASE
Fatty acid profile was related to the activity of the
disease, both in ulcerative colitis (Table IV) and
Crohn's disease patients (Table V). The plasma
values of stearic acid (C18:0) and long chain n3
and n6 polyunsaturated fatty acids decreased
stepwise as the disease became more severe. This
only reached statistical significance for stearic
acid (C18:0) and long chain n6 polyunsaturated
fatty acids in ulcerative colitis and for arachi-
donic acid (C20:4n6) in Crohn's disease.
The decrease in plasma long chain polyun-
saturated fatty acids associated to the increase of
disease activity, was more marked in the n6
series (arachidonic and dihomo-T-linolenic acid),
especially in ulcerative colitis. It is remarkable
that, in spite of the progressive fall in plasma
docosahexaenoic acid values as inflammatory
bowel disease became more severe, its mean
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value always remained above the mean value of
this n3 polyunsaturated fatty acid in healthy
individuals. It is also noteworthy that in mild
disease, concentrations of long n6 polyun-
saturated fatty acids, especially arachidonic acid,
also remained above those in healthy controls.
The decrease in plasma long chain and highly
unsaturated fatty acids in those patients with
more severe disease, which resulted in a signifi-
cant reduction of the unsaturation index, was
partly counterbalanced by a significant increase
in the percentage of oleic acid (C 18: 1).
Discussion
The most striking result of this study is the
increased plasma concentrations of the precursor
(ct-linolenic acid) and the end product (docosa-
hexaenoic acid) of the n3 polyunsaturated fatty
acid series in active ulcerative colitis and Crohn's
disease. In addition, low concentrations of
dihomo-t-linolenic (C20:3n6) acid were also
found. When patients were grouped according to
the severity of the attack, however, a stepwise
fall in polyunsaturated fatty acids was observed
as the disease became more severe. This was
especially marked for long chain n6 polyun-
saturated fatty acids in ulcerative colitis and
Crohn's disease. It is remarkable that although
concentrations of docosahexaenoic acid (C22:
6n3) also tend to decrease stepwise as disease
activity increased, their mean concentrations
never reach values below that of healthy con-
trols.
This pattern of plasma fatty acids suggests
that, in active inflammatory bowel disease,
increased polyunsaturated fatty acid biosyn-
thesis might coexist with increased fatty acid
consumption. The finding of high plasma n3
polyunsaturated fatty acids concentrations
would support the first part of this hypothesis;
that is, the increase in polyunsaturated fatty acid
biosynthesis. This phenomenon would be
particularly evident in this fatty acid series
because n3 polyunsaturated fatty acids are pre-
ferential substrates for desaturases.`336 The fact
that high concentrations of n6 fatty acids were
also observed in patients with mild disease
further supports the concept of an enhanced
polyunsaturated fatty acid biosynthesis in
inflammatory bowel disease.
The second part of the hypothesis - that is, the
excessive consumption of fatty acids, might be
supported by the stepwise fall of stearic acid
(C18:0) and long chain polyunsaturated fatty
acids, particularly those of the n6 series,
observed as disease activity became more severe.
Polyunsaturated fatty acid hypermetabolism
may take place to meet the needs for cellular
repair and to obtain energy (,3-oxidation) as in
other hypercatabolic states.37 38 Another possible
explanation for the more marked decrease in
plasma n6, as compared with n3 polyunsaturated
fatty acids, might be an increased synthesis of
arachidonic acid derived eicosanoids in the
intestinal mucosa in active disease.7'-2 It may be
argued that low essential fatty acid intake could
account for the diminished long chain polyun-
saturated fatty acids in severe disease. Plasma
concentrations of both essential fatty acids,
linoleic (C18:2n6), and at-linolenic (C18:3n3),
however, were not decreased even when disease
was severe. To reinforce the suggestion of an
enhanced polyunsaturated fatty acid synthesis,
counterbalanced by hyperconsumption in active
inflammatory bowel disease, studies have to be
carried out in non-active patients.
A high intake of n3 fatty acids, especially of
the essential ct-linolenic acid, could be postulated
as an explanation for the increased n3 polyun-
saturated fatty acids in inflammatory bowel
disease. This was not the case in our patients,
however, as they were eating a standard western
diet. This type of diet contains negligible
amounts of long chain n3 fatty acids (less than
1% of the total fatty acids consumed).39 In
addition, these patients usually reduce their food
intake when disease flares up. It could then be
speculated that the high concentrations of ct-
linolenic acid (which is exclusively from dietary
origin), might be the result of a negative feed
back effect upon delta-6 desaturase activity,
mediated by an excess of docosahexaenoic acid
(C22:6n3), the final product of this series. 2
The high c6ncentrations of palmitic acid
(C 16:0) in ulcerative colitis suggest an enhanced
lipolysis caused by increased energy require-
ments, as occur in other hypercatabolic
states.4344 In this setting, it is difficult to explain
the low plasma concentrations of stearic acid
(C18:0). It might be speculated that this results
in a diminished synthesis of stearic acid from
palmitic acid (which would be preferentially
oxidated) and/or an increased activity of delta-9-
desaturase to produce oleic acid.
Two previous reports have assessed plasma
polyunsaturated fatty acid pattern in patients
with Crohn's disease. Both studies represent
selected populations of patients with Crohn's
disease as they included patients with either ileal
resection27 or malabsorption.26 In contrast with
our results, these studies describe a pattern of
essential fatty acid deficiency, probably related
to malabsorption. Severe malabsorption seldom
occurs in Crohn's disease.
Two studies45 46 have shown that in inflamma-
tory bowel disease the concentrations of arachi-
donic acid (C20:4n6) in the inflamed colonic
mucosa were increased. Moreover, in one45
increased concentrations of docosahexaenoic
acid (C22:6n3) were also found. These data are in
agreement with our findings, and with the fact
that plasma fatty acid pattern reflects the fatty
acid composition of the tissues.47
The changes in n3 and n6 polyunsaturated
fatty acid profile found in inflammatory bowel
disease may be of relevance in the pathogenesis
of the disease because they influence either tissue
eicosanoid synthesis and the membrane lipid
composition of the immunocompetent cells.48 It
has been demonstrated that in vitro manipula-
tion of fatty acid composition oflymphocytes can
alter immune functions, such as cytotoxicity,
antibody response, or cell to cell recognition.8 49
In this context, the similar polyunsaturated fatty
acids pattern found in ulcerative colitis and
Crohn's disease suggests that both diseases
might share a common pathogenic mechanism.
It would be of interest to know whether this
plasma fatty acid pattern, not previously
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reported in other disease states,50 is exclusive to
inflammatory bowel disease or also occurs in
other autoimmune conditions.
Based on the fact that eicosapentaenoate
derived eicosanoids have attenuated proinflam-
nmatory activity as compared with arachidonate
derived compounds, dietary n3 polyunsaturated
fatty acid supplements (fish oil) have been
successfully used in experimental animal models
of inflammation2' and in patients with rheuma-
toid arthritis.2 According to this hypothesis,
they have been administered in inflammatory
bowel disease patients, but the results of various
clinical trials are controversial.2325 Our finding of
high plasma n3 polyunsaturated fatty acid con-
centrations in active inflammatory bowel disease
raises some doubts on the use of high doses of n3
polyunsaturated fatty acids in the treatment of
inflammatory bowel disease.
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